12:00 AM
 | 
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Brintellix vortioxetine: Additional Phase III data

The double-blind, international Phase III Study 13267A in 603 patients aged 18-75 with MDD showed that once-daily 15 and 20 mg doses of Brintellix each met the primary endpoint of reducing mean MADRS total score from baseline to week 8 vs. placebo (mean treatment differences compared to placebo of 5.6 and 7.1 points, respectively, p<0.0001 for both). Patients...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >